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Abstract 
Thromboxane A 2 (TXA 2) and ET-I have been known to play important roles in modulating vascular contraction and growth. The 
present study was undertaken to examine the effect of TXA 2 on the induction of endothelin-1 (ET-1) mRNA and protein levels in smooth 
muscle cells derived from rat heart. U-46619, a stable TXA 2 mimetic, superinduced preproET-1 mRNA in the presence of cycloheximide 
in these cells. This effect could be blocked by SQ-29548, aTXAE/prostaglandin H 2 receptor antagonist and by actinomycin D, an RNA 
synthesis inhibitor. In addition, H7, a protein kinase C inhibitor, could abolish the induction. Transient transfection experiment revealed 
that the elevated ET-1 mRNA level after U-46619 treatment was a result of the activation of ET-1 gene activity. The elevated ET-1 
message l vel was accompaJaied by increased ET-I release into the cultured medium. These results show that the short-lived TXA 2 can 
induce potent and long-lived ET-1. These findings support a potential role for ET-1 in the pathogenesis of coronary atherosclerosis and 
hypertension evoked by TXA 2. 
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1. Introduction 
Thromboxane A z (TXA2) is a cyclooxgenase metabo- 
lite of arachidonic acid [1]. It is one of the most potent 
biological stimuli of platelet aggregation and smooth mus- 
cle contraction and has been implicated as an important 
pathophysiological mediator of various cardiovascular dis- 
eases [2,3]. Since thromboxane A 2 has a very short half-life 
in the blood (less than 30 s), it is possible that part of the 
vascular activities of TXA 2 may be mediated by ET-1, a 
long-acting vasoconstrictor. 
Endothelin-I (ET-l) is a very potent vasoconstrictor 
that has been initially isolated from the supematant of 
cultured porcine endothelial cells [4]. The mRNA for 
preproET-I is expressed in porcine aortic endothelial cells 
in vivo [5] and porcine ;aortic endothelial cells and human 
umbilical vein endothelial cells in vitro [4,6]. Many 
physiological stimuli were found to increase ET-1 produc- 
tion and mRNA level, including thrombin [7], calcium 
ionophore [4], tumor promoter [8], insulin [9], bradykinin 
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[10], cytokines uch as transforming rowth factor-[~ [11] 
and interleukin 1 [12]. More recently, we reported that 
angiotensin II stimulated ET-I production in rat heart 
endothelial cells [13]. 
The present experiments were carried out in rat heart 
smooth muscle cells to examine the effect of TXA 2 on the 
induction of preproET-1 transcripts, which is a key regula- 
tory step in the production of ET-1. Our results show that 
exposure to the TXA 2 mimetic U-46619 is associated with 
a rapid rise of preproET-I mRNA in smooth muscle cells. 
The increase in the expression and release of ET-I may 
augment or prolong the actions of TXA 2. 
2. Materials and methods 
2.1. Cell culture and materials 
Smooth muscle cells derived from rat heart were pro- 
vided by Diglio et al. [14]. Cells were cultured in Dul- 
becco's modified Eagle's medium (DMEM, Life Tech- 
nologies) containing 10% fetal bovine serum (FBS), 2 mM 
L-glutamine, and 25 I.Lg/ml gentamycin at 37°C in a 
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humidified atmosphere of 5% CO 2 . Cells were serially 
subcultured by treatment with trypsin (0.05% trypsin in 0.5 
mM Versene) and used for experimentation between pas- 
sages 12 and 25. The homogeneity of the cell population 
was confirmed by immunofluorescence staining with 
smooth muscle o~-actin (BioGenex, San Ramon, CA). U- 
46619 and endothelin ELISA kit were purchased from 
Cayman Chemical Company (Ann Arbor, MI). SQ-29548 
was a gift from Bristol-Myers Squibb. H7 was obtained 
from Sigma Chemical Company. [32 p] dCTP was obtained 
from ICN. ITS was purchased from Collaborative Biomed- 
ical (Bedford, MA). Fetal bovine serum was obtained from 
Biofluids. All other reagents used were of the highest 
grade commercially available. 
2.2. Northern blot analysis 
Cells were seeded into 100 mm dishes containing 
DMEM and 10% FBS. Near confluent cells were changed 
to serum-free DMEM supplemented with ITS (1 IxM 
insulin, 6.25 i, tg /ml  transferrin and 6.25 ng/ml selenous 
acid) for 24 h before the addition of test agents. After the 
designated time total RNA was extracted using the acid 
guanidinium thiocyanate-phenol-CHCl 3 extraction method 
[15]. Fifteen I, zg of RNA was denatured and separated by 
electrophoresis on 1% agarose gel containing 2.2 M 
formaldehyde. RNA ladder (BRL) was included as size 
marker. Following transfer, the RNA was covalently bound 
to Nytran (Schleicher and Schull) by UV-crosslinking. 
Hybridization and washing conditions were carried out 
according to the method of Church and Gilbert [16]. A rat 
ET- 1 probe was generously provided by Dr. Tomoh Masaki 
and Dr. M. Yanagisawa (Kyoto University) [17], and a rat 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
probe was provided by Dr. Ray Wu (Cornell University). 
The cDNAs were labeled with [32 p] dCTP using a random 
primer kit from Amersham. The blots were exposed to 
XAR-5 films with an intensifying screen. The intensity of 
the bands was quantitated by using the Ambis Image 
Analysis System. The experiments were repeated three to 
four times and representative data were shown. 
2.3. ET-1 promoter actiL'ib' 
ing the same amount of protein were assayed for CAT 
activities as described by Gorman et al. [20]. CAT activity 
was quantitated by counting the radioactivity excised from 
the spots corresponding to chloramphenicol and acetylated 
chloramphenicol. 
2.4. Secreted let'els o f  ET- I  
Rat heart smooth muscle cell cultures were plated in 
DMEM containing 10% FBS in 35 mm dishes. Near 
confluent cells were maintained in serum-free DMEM with 
the addition of ITS (1 txM insulin, 6.25 Ixg/ml transferrin 
and 6.25 ng/ml selenous acid) for 24 h before the addition 
of 1 • 10  -7 M U-46619 for 8 h and 12 h. ET-1 released into 
the medium was measured using an endothelin ELISA kit. 
2.5. Statistical analysis 
Statistical analysis was made by the Student's test for 
comparison of any two sample means. P values less than 
0.05 were considered statistically significant. 
3. Results 
Steady-state l vels of preproET-I mRNA were deter- 
mined in rat heart smooth cell cultures by Northern blot 
analysis. The basal level of preproET-1 mRNA was low. 
The mRNA level increased rapidly upon the addition of 
U-46619, a stable TXA~ mimetic [21]. Levels of pre- 
proET-1 mRNA increased 5-fold at 30 min (Fig. 1, lane 2) 
and declined over 2 h (lane 4). The same blot was reprobed 
with a cDNA encoding GAPDH as an internal control to 
correct for varying loading and/or transfer. As shown in 
Fig. 2, preproET-I mRNA responded to U-46619 in a 
dose-dependent manner. 
The next series of experiments were performed to ex- 
amine the mechanism of preproET-I RNA induction. In- 
hibitors of protein and RNA synthesis were included singly 
or in combination with U-46619. In the presence of actino- 
mycin D, the induction was abolished (Fig. 3, lane 4), 
suggesting that de novo RNA synthesis is required. Cyclo- 
heximide was included to examine whether the induction 
Rat aortic smooth muscle cells (passage 5, provided by 
Dr. K.S. Ramos, Texas A and M University) [18] in 60 
mm plates were transiently transfected with 5 I~g of 4.4 
Kb ET- I promoter coupled to chloramphenicol acetyltrans- 
ferase gene (provided by Dr. Mu-En Lee, Harvard Medical 
School) [19], pSV2CAT, or pSVOCAT. Transfection was 
carried out with 40 txg of Lipofectin reagent in the pres- 
ence of Opti-MEM (Life Technologies) for 16 h. The 
medium was changed to DMEM containing 10% FBS for 
24 h. The cultures were then incubated with serum-free 
DMEM in the presence or absence of 1 • 10  -7  M U-46619. 
After 36 h, cell lysates were prepared and aliquots contain- 
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Fig. 1. Time-course of ET-I mRNA induction i rat heart smooth muscle 
cells by U-46619. Near confluent cultures were exposed to U-46619 
(1" 10 -7 M) for the times indicated. 15 txg of total RNA was hybridized 
with a cDNA probe for rat ET-I. Hybridization patterns ofcells treated 
with U-46619 for 0 min (lane I); 30 min (lane 2); 1 h (lane 3); 2 h (lane 
4): 3 h (lane 5); 4 h (lane 6); are shown. 
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Fig. 2. Induction of ET-I mRNA as a function of U-46619 dose. Near 
confluent cultures of rat heart smooth muscle cells were treated with 
1-10 -~ M to 1-10 -6 M of U-46619 for 1 h. 15 ~g of total RNA was 
hybridized with a cDNA probe for rat ET-1. Hybridization patterns of 
control cells (lane 1); cells treated with 1.10 -t l  M U-46619 (lane 2): 
1-10 - I°  M 46619 (lane 3); 1.10 -9 M U-46619 (lane 4); 1.10 -8 M 
U-46619 (lane 5); 1 • 10-7M U-46619 (lane 6): 1.10 -6 M U-46619 (lane 
7): are shown. 
Fig. 4. Effect of SQ-29548, an antagonist of U-46619, on the induction of 
ET-1 mRNA. Total RNA was isolated from rat heart smooth muscle cell 
cultures in the absence or presence of SQ-29548 and U-46619. Hybridiza- 
tion patterns of control cells (lane 1): cells treated with 1.10 -7 M 
U-46619 (lane 2): 1.10 -7 M SQ-29548 (lane 3): 1.10 -6 M SQ-29548 
(lane 4); 1.10 -5 M SQ-29548 (lane 5); 1.10 -7 M SQ-29548 and 
U-46619 (lane 6), 1.10 -6 M SQ-29548 and U-46619 (lane 7): 1-10 -5 
M SQ-29548 and U-46619 (lane 8); are shown. 
of ET-I gene is a direct effect of U-46619 or whether 
intermediate protein synthesis is required. Cycloheximide 
alone induced preproET-1 mRNA (lane 5). In the presence 
of U-46619 and cycloheximide (lane 6), the induction was 
higher than U-46619 alone (lane 2), implying that the 
induction does not require de novo protein synthesis. 
SQ-29548, a specific antagonist for TXA 2 receptor 
[22], was included to examine if the effect of U-46619 is 
receptor-mediated. A dose curve of SQ-29548 was per- 
formed. SQ-29548 alone did not affect the preproET-1 
mRNA level (Fig. 4, lanes 3-5). The induction of pre- 
proET-1 mRNA by U-46619 was diminished with increas- 
ing concentrations of SQ-29548 (lanes 5-8). These results 
indicate that the induction of preproET-I mRNA is medi- 
ated by the TXA2 receptor. 
To study if the induction of preproET-I mRNA in- 
volves a protein kinase C -dependent pathway, H7, a 
protein kinase C inhibitor [23], was included. In these 
experiments, cells were l:.retreated with 1 tzM H7 for 30 
min before the addition of U-46619. H7 could block the 
induction of preproET-1 mRNA (Fig. 5, lane 4), suggest- 
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Fig. 3. Effect of cycloheximide (CHX) and actinomycin D (Act D) on the 
induction of ET-1 mRNA by U-46619. Near confluent cultures of rat 
heart smooth muscle cells were treated with U-46619 for 1 h in the 
absence or presence of Act D (1 Ixg/ml) or CHX (20 Ixg/ml). 15 txg of 
total RNA was hybridized with rat ET-1 cDNA probe. Hybridization 
patterns of control cells (lane 1); cells treated with 1.10 -7 M U-46619 
(lane 2); Act D (lane 3); U-46619 and Act D (lane 4); CHX (lane 5); 
U-46619 and CHX (lane 6); are shown. 
ing that the effect of TXA 2 is mediated by a protein kinase 
C-dependent pathway. 
Expression of elevated ET-I mRNA level after U-46619 
treatment may be the result of increased stability of the 
message and/or activation of ET-1 gene activity. To test if 
the transcription rate of ET-I is altered by U-46619, 
transfection experiments were carried out with ET-I pro- 
moter coupled to the CAT gene in the absence or presence 
of U-46619. Fig. 6 shows that U-46619 increased CAT 
"l- 
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Fig. 5. Effect of protein kinase C inhibitor, H7, on the induction of ET-I 
mRNA by U-46619. Near confluent rat heart smooth muscle cells were 
pretreated with H7 for 30 rain before the addition of U-46619 for 1 h. 
Hybridization patterns of control cells (lane 1): cells treated with I. 10 -7 
M U-46619 (lane 2); 1 IxM H7 (lane 3); U-46619 and H7 (lane 4): are 
shown. 
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Fig. 6. Stimulation of ET-1 promoter activity by U-46619. Rat aortic 
smooth muscle cells in 60 mm plates were transfected with 5 l, tg of either 
pSV2CAT, pSVOCAT or ET-1 promoter (-4.4kCAT) and 40 Izg of 
Lipofectin for 16 h. The medium was then changed to DMEM in the 
presence or absence of 1 - 10 -7 M U-46619 for 36 h prior to harvest for 
CAT assays. CAT activity of cells transfected with pSV2CAT (lanes 1,2), 
pSVOCAT (lanes 3,4), and ET-1 promoter (lanes 5,6), are shown. Lanes 
1,3,5 represent he pattern in the absence of U-46619; lanes 2,4,6 
represent the pattern in the presence of U-46619. 
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Fig. 7. Release of  ET- l into the medium of rat heart smooth muscle cells. 
Quiescent rat heart smooth muscle cells were incubated with 1 • 10 -7 M 
U-46619 for 8 h and 12 h. ET-I released into the medium was measured 
by ELISA. Values represent the mean+ S.E.M. of  four samples. * P < 
0.05 vs. control. 
activity of ET-1 promoter fourfold (lanes 5,6). U-46619 
had no effect on the CAT activities in cells transfected 
with pSV2CAT (lanes 1,2) or pSVOCAT (lanes 3,4). 
The release of ET-1 in response to U-46619 was deter- 
mined in the conditioned medium by ELISA. After stimu- 
lation with 1 • 10  -7  M U-46619 for 8 h, the control cells 
released 17 ± 6 pg ET- 1/well whereas the value for stim- 
ulated cells was 66 + 11 pg/well. After 12 h, the control 
value was 51 +_ 10 pg/well  whereas the stimulated cells 
gave 325 ___ 10 pg/well  (Fig. 7). 
4. Discussion 
The present study demonstrated that TXA 2 mimetic 
U-46619 acts on rat heart-derived smooth muscle cells to 
induce preproET-1 mRNA in a dose and time dependent 
manner. The induction is mediated by the TXA2/PGH 2 
receptor and involves a protein kinase C dependent path- 
way. In addition, the increase of ET-1 mRNA correlated 
well with the release of ET- 1 into the conditioned medium. 
It is noted that induction of preproET-I mRNA begins 
with 1 • 10 -8 M U-46619. This concentration is compara- 
ble to the concentrations u ed in other assays such as the 
induction of constriction of rat aorta [24] and the mitogenic 
effect on rat vascular smooth muscle cells [25]. 
In this study preproET-I mRNA induction elicited by 
U-46619 was shown to be diminished with increasing 
concentrations of SQ-29548. SQ-29548 has been reported 
to be a specific TXAz/PGH 2 receptor antagonist [22]. 
SQ-29548 at 1 IxM could block the contraction of rat 
aortic ring elicited by 1 • 10  -7  M U-46619 [26] and sup- 
press its mitogenic effect in rat vascular smooth muscle 
cells [25]. 
Our data demonstrated that the induction of preproET- 1
mRNA by U-46619 could be attributed partially to tran- 
scriptional activation. Although the elements responsible 
for this activation were not characterized in the present 
study, the promoter of the ET-1 gene has been shown to 
contain AP- 1 sites [ 19,27]. Whether the effect of U-46619 
is mediated by the AP-1 element in our cell system is 
under investigation. It is interesting to note that preproET- 1
mRNA is 'superinduced' in the presence of cycloheximide 
and U-46619. The level of preproET-1 mRNA in the 
presence of cycloheximide alone is higher than the basal 
level. Yanagisawa et al. [1] reported the 3'-end of pre- 
proET-I mRNA contains several 'AUUUA' motifs that 
confer mRNA instability. Cycloheximide might inhibit the 
synthesis of labile proteins with RNase activities or short- 
lived repressors. 
Our results showed that H7, a protein kinase C in- 
hibitor, could block the induction of preproET-1 mRNA by 
U-46619. This observation concurred with the previous 
report that TXA 2 activates phospholipase C in vascular 
smooth cells leading to the production of IP 3, increased 
Ca 2+ mobilization from the intracellular store and in- 
creased protein kinase C activity [28]. 
It is well established that TXA 2 and prostacyclin (PGI 2) 
are involved in the control of vascular tone and hemostasis 
via a reciprocal function in blood-endothelium interactions. 
There is compelling evidence to support he possible in- 
volvement of TXA 2 in the pathogenesis of severe hyper- 
tension. The biosynthesis of TXA 2 is increased in several 
models of experimental hypertension [29-34]. The devel- 
opment of hypertension could be attenuated by administra- 
tion of thromboxane synthase inhibitors or TXA2 antago- 
nists [29,30,35,36]. 
TXA 2 has also been suggested to participate in the 
promotion of atherosclerosis. TXA 2 is secreted in large 
amounts by activated platelets during the development of
atherosclerosis and acute myocardial ischemia [37,38]. Be- 
sides its prominent action on platelet activation, TXA 2 has 
been shown to have a mitogenic effect on rat aortic smooth 
muscle cells [39,40]. Our preliminary experiments showed 
that in rat heart smooth cells, both TXA 2 and ET-1 could 
increase the incorporation of [3H] thymidine into DNA by 
two- and three-fold, respectively (results not shown). The 
proliferative activities of rat heart smooth muscle cells in 
response to TXA 2 may be one of the underlying mecha- 
nisms leading to coronary artery disease. 
In conclusion, we present evidence that ET-1 is rapidly 
induced by TXA 2 in rat heart smooth muscle cells. ET-1 
has been shown to stimulate TXA 2 biosynthesis n smooth 
muscle cells [41]. These interesting interactions between 
TXA 2 and ET-1 might serve to amplify and perpetuate he 
effect of TXA 2 on both coronary constriction and the 
development of atherosclerosis under pathophysiological 
conditions. 
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